China NMPA Product Recall - Fosfomycin calcium capsules

The National Medical Products Administration (NMPA), through its provincial arm, the Jiangxi Provincial Food and Drug Administration, has ordered a product recall impacting Jiangxi Xinganjiang Pharmaceutical Co., Ltd. The action stems from recent drug supervision and inspection activities where regulatory authorities identified significant quality deficiencies with the company's fosfomycin calcium capsules. While specific inspection dates are not detailed, the discovery of these quality problems prompted immediate regulatory intervention to protect public health and ensure medication safety. Consequently, the Jiangxi Provincial Food and Drug Administration has mandated the immediate recall of all affected fosfomycin calcium capsules produced and sold by Jiangxi Xinganjiang Pharmaceutical Co., Ltd. Furthermore, the administration indicated that the matter would be handled in accordance with established legal procedures, suggesting potential further enforcement actions beyond the recall. This directive underscores the NMPA's commitment to upholding rigorous pharmaceutical quality standards and ensuring the efficacy and safety of drugs in the market.